STAT1 and toxoplasmosis: Contrastingly, the reports in the literature for STAT1 GOF on JAKinib mention higher rates of urinary infections [27, 28] and other less frequent infectious complications, such as herpes virus reactivation [28], tuberculosis and/or other atypical mycobacterial infections [27–29], JC virus (four fatal cases) [30–33], Pneumocystis jirovecii [34], hepatitis B [35, 36], and toxoplasmosis [37].